Myriad Genetics (NASDAQ:MYGN) Stock Price Target Raised at Leerink Partners

Posted by Stanley Muller on Nov 5th, 2026

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price increased by equities researchers at Leerink Partners from $5.00 to $8.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “market perform” rating on the stock. Leerink Partners‘s price target would indicate a potential upside of 28.51% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Myriad Genetics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Stephens decreased their price objective on shares of Myriad Genetics from $5.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 18th. Weiss Ratings downgraded shares of Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 27th. Wells Fargo & Company set a $4.50 price objective on shares of Myriad Genetics in a research note on Tuesday, October 20th. Finally, TD Cowen raised their target price on Myriad Genetics from $4.00 to $4.50 and gave the stock a “hold” rating in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Myriad Genetics presently has a consensus rating of “Hold” and a consensus target price of $5.23.

Check Out Our Latest Report on MYGN

Myriad Genetics Stock Performance

Shares of MYGN stock traded up $0.20 during trading on Thursday, hitting $6.22. The company’s stock had a trading volume of 2,211,760 shares, compared to its average volume of 1,895,261. The company has a market cap of $595.42 million, a PE ratio of -5.27 and a beta of 1.62. The company has a current ratio of 2.21, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40. The business has a fifty day moving average of $4.38 and a 200-day moving average of $4.62. Myriad Genetics has a 52 week low of $2.74 and a 52 week high of $8.09.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.09. The business had revenue of $202.70 million for the quarter, compared to the consensus estimate of $191.33 million. Myriad Genetics had a negative return on equity of 16.09% and a negative net margin of 13.96%. As a group, research analysts anticipate that Myriad Genetics will post -0.99 earnings per share for the current year.

Institutional Trading of Myriad Genetics

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Myriad Genetics during the 2nd quarter valued at $62,184,000. Bank of America Corp DE bought a new stake in Myriad Genetics in the second quarter worth $5,150,000. Bank of New York Mellon Corp purchased a new position in Myriad Genetics during the second quarter worth $1,930,000. Orbimed Advisors LLC purchased a new position in Myriad Genetics during the first quarter worth $562,500,000. Finally, Man Group plc bought a new position in Myriad Genetics during the second quarter valued at $5,189,000. Institutional investors own 99.02% of the company’s stock.

Key Stories Impacting Myriad Genetics

Here are the key news stories impacting Myriad Genetics this week:

Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, up 6% sequentially, and a loss of $0.11 per share—narrower than analysts’ expected $0.20 loss. Revenue also exceeded estimates. Read More.
Positive Sentiment: The company raised the midpoint of its 2026 revenue guidance, citing execution and improved revenue per test. It also agreed to sell its Prenatal Health business for $210 million, a transaction Myriad says will support strategic growth initiatives. Read More.
Neutral Sentiment: Q3 revenue was still 1% lower year over year, while test volume declined 2% year over year. Higher average revenue per test partly offset the volume weakness. Read More.
Negative Sentiment: Myriad said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential data exposure could create operational, legal, or reputational risks. Read More.

Myriad Genetics Company Profile

(Get Free Report)

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.